{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T17:22:59Z","timestamp":1696008179849},"reference-count":110,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":5715,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1093\/annonc\/mdh094","type":"journal-article","created":{"date-parts":[[2004,4,26]],"date-time":"2004-04-26T18:53:19Z","timestamp":1083005599000},"page":"703-711","source":"Crossref","is-referenced-by-count":7,"title":["Challenging paradigms in lymphoma treatment"],"prefix":"10.1016","volume":"15","author":[{"given":"M.","family":"Bendandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.L.","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh094_bb0010","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European\u2013American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0015","series-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"157","article-title":"Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","author":"Isaacson","year":"2001"},{"key":"10.1093\/annonc\/mdh094_bb0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdh094_bb0025","first-page":"25","article-title":"Follicular Lymphoma International Prognostic Project (FLIPP)","volume":"13","author":"Solal-Celigny","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0102-68","article-title":"Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning","volume":"8","author":"Shipp","year":"2002","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdh094_bb0035","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh094_bb0040","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh094_bb0045","first-page":"630","article-title":"Stanford V and radiation treatment for locally extensive and advanced Hodgkin\u2019s disease: mature results of a prospective clinical trial","volume":"20","author":"Horning","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0050","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2002.20.3.607","article-title":"New treatments for advanced Hodgkin\u2019s disease: an uphill fight beginning close to the top","volume":"20","author":"Canellos","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0055","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"Diehl V. A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh094_bb0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/13.S1.75","article-title":"The disappearance of prognostic factors in Hodgkin\u2019s disease","volume":"13","author":"Hasenclever","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0065","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jnci\/95.13.928","article-title":"Radiation therapy in the treatment of Hodgkin\u2019s disease: do you see what I see?","volume":"95","author":"Longo","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdh094_bb0070","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.leu.2401737","article-title":"Long-term follow-up of advanced-stage low-grade lymphoma patients treated up front with high-dose sequential chemotherapy and autograft","volume":"14","author":"Tarella","year":"2000","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdh094_bb0075","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V97.2.404","article-title":"High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial","volume":"97","author":"Horning","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0080","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V88.7.2780.bloodjournal8872780","article-title":"High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission","volume":"88","author":"Freedman","year":"1996","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood.V99.1.75","article-title":"Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies","volume":"99","author":"Corradini","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0090","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2000.18.23.3918","article-title":"Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma","volume":"18","author":"Carella","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0095","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1200\/JCO.2001.19.22.4238","article-title":"Phase III randomized intergroup trial of subtotal lymphoid irrdiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin\u2019s disease","volume":"19","author":"Press","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0100","first-page":"476","article-title":"Rapidly alternating COPP\/ABV\/IMEP is not superior to conventional alternating COPP\/ABVD in combination with extended-field radiation treatment in intermediate-stage Hodgkin\u2019s lymphoma: final results of the German Hodgkin\u2019s Lymphoma Study Group Trial HD5","volume":"20","author":"Sieber","year":"2002","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdh094_bb0105","first-page":"25","article-title":"ABVD vs Stanford V vs MOPP-EBV-CAD in advanced Hodgkin\u2019s lymphoma","volume":"13","author":"Levis","year":"2002","journal-title":"Results of a randomized trial. Ann Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0110","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2002.11.107","article-title":"ChlVPP\/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin\u2019s disease","volume":"20","author":"Radford","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0115","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1200\/JCO.2003.07.160","article-title":"Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin\u2019s disease: a report from the German Hodgkin\u2019s Lymphoma Study Group","volume":"21","author":"Josting","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0120","first-page":"729","article-title":"Efficacy of the VBM regimen in the treatment of elderly patients with Hodgkin\u2019s disease","volume":"85","author":"Zinzani","year":"2000","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdh094_bb0125","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood.V98.10.2930","article-title":"Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease","volume":"98","author":"Weihrauch","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0130","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdf256","article-title":"Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"13","author":"Spaepen","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0135","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved-field radiotherapy for advanced Hodgkin\u2019s lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh094_bb0140","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V96.4.1280","article-title":"Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group","volume":"96","author":"Josting","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0145","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s Lymphoma Study Group","volume":"20","author":"Josting","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0150","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomized trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdh094_bb0155","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh094_bb0160","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiation treatment for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdh094_bb0165","first-page":"92a","article-title":"Radiotherapy is unnecessary in elderly patients with localized aggresive non-Hodgkin\u2019s lymphoma results of GELA LNH 93-4 study","volume":"100","author":"Fillet","year":"2002","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdh094_bb0170","first-page":"724a","article-title":"CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin\u2019s lymphoma update of the Southwest Oncology Group (SWOG) randomized trial","volume":"98","author":"Miller","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0175","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin\u2019s lymphoma","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0180","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh094_bb0185","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood.V97.10.2991","article-title":"Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO","volume":"97","author":"Mainwaring","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0190","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/cncr.10583","article-title":"International Prognostic Index-based outcomes for diffuse large B-cell lymphomas","volume":"94","author":"Wilder","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh094_bb0195","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0200","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood.V99.7.2285","article-title":"The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile","author":"Huang","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0205","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V99.3.815","article-title":"De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients","volume":"99","author":"Yamaguchi","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0210","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1535-6108(02)00178-2","article-title":"Focus on lymphomas","volume":"2","author":"Staudt","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdh094_bb0215","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0002-9343(01)01117-2","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin\u2019s disease and non Hodgkin\u2019s lymphoma","volume":"112","author":"Wirth","year":"2002","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdh094_bb0220","first-page":"2274a","article-title":"18F-fluorodesoxyglucose positron emission tomography (FDG-PET) in aggressive non-Hodgkin\u2019s lymphoma (NHL) an early prognostic tool for predicting patient outcome","volume":"22","author":"Haioun","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0225","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0230","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V77.7.1587.1587","article-title":"PARMA International Protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation","volume":"77","author":"Philip","year":"1991","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0235","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood.V96.7.2399","article-title":"High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis","volume":"96","author":"Kewalramani","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0240","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","article-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin\u2019s lymphoma: final analysis of the prospective LNH87-2 protocol\u2014a Groupe d\u2019Etude des Lymphomes de l\u2019Adulte study","volume":"18","author":"Haioun","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0245","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1200\/JCO.2002.09.138","article-title":"Autologous transplantation for aggressive non-Hodgkin\u2019s lymphoma: results of a randomized trial evaluating graft source and minimal residual disease","volume":"20","author":"Vose","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0250","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/sj.leu.2402302","article-title":"Concomitant administration of high-dose chemotherapy and rituximab is a feasible and effective chemo\/immunotherapy for patients with high-risk non-Hodgkin\u2019s lymphoma","volume":"15","author":"Ladetto","year":"2001","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdh094_bb0255","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.1998.16.8.2796","article-title":"VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin\u2019s lymphoma: results of a prospective randomized trial by the non-Hodgkin\u2019s lymphoma cooperative study group","volume":"16","author":"Santini","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0260","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","article-title":"Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma","volume":"102","author":"Hamlin","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0265","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1182\/blood-2003-01-0095","article-title":"Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed\/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation","volume":"102","author":"Laport","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0270","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0275","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0280","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10428190009053541","article-title":"Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients","volume":"39","author":"Romaguera","year":"2000","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdh094_bb0285","first-page":"3030a","article-title":"Mantle cell lymphoma (MCL)high rates of complete remission (CR) and prolonged failure-free survival (FFS) with Rituxan-hyperCVAD (R-HCVAD) without stem cell transplant (SCT)","volume":"98","author":"Romaguera","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0290","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdh094_bb0295","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0300","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br J Haematol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdh094_bb0305","first-page":"9","article-title":"Phase II study of idiotype vaccine following EPOCH-Rituximab treatment in untreated mantle-cell lymphoma","volume":"13","author":"Wilson","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0310","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1586\/14737140.1.1.65","article-title":"Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma","volume":"1","author":"Bendandi","year":"2001","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1093\/annonc\/mdh094_bb0315","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00000421-200208000-00015","article-title":"Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-Hodgkin\u2019s lymphoma","volume":"25","author":"Lynch","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0320","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood.V100.4.1141.h81602001141_1141_1152","article-title":"Intensive therapies in follicular non-Hodgkin lymphomas","volume":"100","author":"Hunault-Berger","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0325","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","article-title":"High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin\u2019s lymphoma: a case-matched study from the European Bone Marrow Transplant Registry","volume":"19","author":"Williams","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0330","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.bmt.1703573","article-title":"Allogenic hematopoietic stem cell transplantation for progressive follicular lymphoma","volume":"29","author":"Forrest","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdh094_bb0335","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","article-title":"Nonablative allogenic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality","volume":"98","author":"Khouri","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0340","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","article-title":"Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma","volume":"95","author":"Hainsworth","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0345","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0350","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0355","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/sonc.2002.30152","article-title":"Rituximab in combination with CHOP or fludarabine in low-grade lymphoma","volume":"29","author":"Czuczman","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0360","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1046\/j.1365-2141.2002.03535.x","article-title":"Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin\u2019s lymphoma","volume":"117","author":"Friedberg","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdh094_bb0365","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0370","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0375","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0380","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0385","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM199210223271705","article-title":"Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors","volume":"327","author":"Kwak","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh094_bb0390","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/13928","article-title":"Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma","volume":"5","author":"Bendandi","year":"1999","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdh094_bb0395","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V89.9.3129","article-title":"Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma\u2014long-term results of a clinical trial","volume":"89","author":"Hsu","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0400","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11864-002-0030-3","article-title":"Vaccine therapies for non-Hodgkin\u2019s lymphoma","volume":"3","author":"Timmermann","year":"2002","journal-title":"Curr Treat Options Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0405","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","article-title":"Idiotype-pulse dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients","volume":"99","author":"Timmermann","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0410","first-page":"783","article-title":"Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases","volume":"95","author":"Federico","year":"2000","journal-title":"Intergruppo Italiano Linfomi. Blood"},{"key":"10.1093\/annonc\/mdh094_bb0415","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3","article-title":"Malignant of mucosa-associated lymphoid tissue: a distinctive type of B-cell lymphoma","volume":"52","author":"Isaacson","year":"1983","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh094_bb0420","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1002\/1097-0142(19840601)53:11<2515::AID-CNCR2820531125>3.0.CO;2-C","article-title":"Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue","volume":"53","author":"Isaacson","year":"1984","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh094_bb0425","first-page":"14","article-title":"Extranodal lymphomas: the MALT concept","volume":"76","author":"Isaacson","year":"1992","journal-title":"Verh Dtsch Ges Pathol"},{"key":"10.1093\/annonc\/mdh094_bb0430","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/oxfordjournals.annonc.a059177","article-title":"The MALT lymphoma concept updated","volume":"6","author":"Isaacson","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0435","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.V96.2.410","article-title":"The gastric marginal zone B-cell lymphoma of MALT type","volume":"96","author":"Zucca","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0440","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0046-8177(88)80287-9","article-title":"Primary B cell lymphoma of the thyroid and its relationship to Hashimoto\u2019s thyroiditis","volume":"19","author":"Hyjek","year":"1988","journal-title":"Hum Pathol"},{"key":"10.1093\/annonc\/mdh094_bb0445","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0046-8177(88)80259-4","article-title":"Primary B-cell lymphoma of salivary glands and its relationship to myoepithelial sialaenitis","volume":"19","author":"Hyjek","year":"1988","journal-title":"Hum Pathol"},{"key":"10.1093\/annonc\/mdh094_bb0450","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.1997.15.4.1624","article-title":"Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: Analysis of 108 patients","volume":"15","author":"Thieblemont","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0455","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V95.3.802.003k19_802_806","article-title":"Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed","volume":"95","author":"Thieblemont","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0460","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.1999.17.4.1254","article-title":"Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients","volume":"17","author":"Zinzani","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0465","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1023\/A:1008282818705","article-title":"Primary extranodal non-Hodgkin\u2019s lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas","volume":"8","author":"Zucca","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0470","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1023\/A:1008313229892","article-title":"Primary extranodal non-Hodgkin\u2019s lymphomas. Part 2: Head and neck, central nervous system and other less common sites","volume":"10","author":"Zucca","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh094_bb0475","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00000478-199201000-00011","article-title":"Primary lymphoma of the trachea with morphologic and immunophenotypic characteristics of low-grade B-cell lymphoma mucosa-associated lymphoid tissue","volume":"16","author":"Kaplan","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdh094_bb0480","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2559.1995.tb00246.x","article-title":"Pulmonary B-cell non-Hodgkin\u2019s lymphomas: the value of immunohistochemistry and gene analysis in diagnosis","volume":"26","author":"Nicholson","year":"1995","journal-title":"Histopathology"},{"key":"10.1093\/annonc\/mdh094_bb0485","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00000478-199004000-00005","article-title":"Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue arising in the thymus: a thymic lymphoma mimicking myoepithelial sialadenitis","volume":"14","author":"Isaacson","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdh094_bb0490","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/00000478-199306000-00005","article-title":"Breast lymphoma a B-cell spectrum including the low-grade B-cell lymphoma of mucosa accosiated lymphoid tissue","volume":"17","author":"Mattia","year":"1993","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdh094_bb0495","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00000478-199608000-00010","article-title":"Marginal zone lymphoma (low grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue","volume":"20","author":"Bailey","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdh094_bb0500","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00000478-199505000-00009","article-title":"Primary low-grade hepatic B-cell lymphoma of mucosa-associated lymphoid tissue (MALT)-type","volume":"19","author":"Isaacson","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdh094_bb0505","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/path.1711740106","article-title":"Mucosa-associated lymphoid tissue (MALT) in the human conjunctiva","volume":"174","author":"Wotherspoon","year":"1994","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdh094_bb0510","first-page":"780","article-title":"Low-grade B-cell lymphoma of mucosa-associated lymphoid tiddue arising in the kidney","volume":"117","author":"Parveen","year":"1993","journal-title":"Arch Pathol Lab Med"},{"key":"10.1093\/annonc\/mdh094_bb0515","first-page":"241","article-title":"Malt lymphomas. Hematology (Am Soc Hematol Educ","author":"Cavalli","year":"2001","journal-title":"Program"},{"key":"10.1093\/annonc\/mdh094_bb0520","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0360-3016(01)02714-6","article-title":"Treatment outcome of mucosa-associated lymphoid tissue\/marginal zone non-Hodgkin\u2019s lymphoma","volume":"52","author":"Hitchcock","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdh094_bb0525","first-page":"1591","article-title":"Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection","volume":"345","author":"Bayerdorffer","year":"1995","journal-title":"MALT Lymphoma Study Group. Lancet"},{"key":"10.1093\/annonc\/mdh094_bb0530","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(00)03571-6","article-title":"Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy","volume":"357","author":"Liu","year":"2001","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdh094_bb0535","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/gast.2002.33047","article-title":"t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication","volume":"122","author":"Liu","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1093\/annonc\/mdh094_bb0540","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood.V98.4.1182","article-title":"t(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10","volume":"98","author":"Liu","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0545","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V99.1.3","article-title":"Gastric marginal zone B-cell lymphomas of MALT type develop along two distinct pathogenetic pathways","volume":"99","author":"Starostik","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh094_bb0550","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0002-9440(10)64157-0","article-title":"Mucosa-associated lymphoid tissue lymphomas with t(11;18)(q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways","volume":"161","author":"Remstein","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdh094_bb0555","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419557672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419557672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/5\/703\/462600\/mdh094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T22:54:21Z","timestamp":1582239261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419557672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":110,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0923753419557672"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh094","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}